Background

The OTM files 70% of its patent applications “at risk” (with no licensee in hand) and recovers about 75% of its patent costs annually through direct licensee reimbursement.

The OTM licenses over 30% of the inventions it evaluates.

As of June 30, 2010

• 1,416 active inventions under management
• 711 active US patents
• 347 active licenses
• 13 drug and medical device technologies in clinical development
• 78 life science start-ups

FDA-Approved Products

• Recombivax® – hepatitis B vaccine (Merck)
• Menostar® - osteoporosis (Schering A.G.)
• Qutenza® - neuropathic pain (NeurogesX, a UCSF start-up)
• EpiCeram® - topical skin cream for eczema and atopic dermatitis (PuraCap Pharmaceutical, LLC)